

FIGURE I




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9





FIGURE 10



*** $p < 0.001$, vibegron vs placebo
Full Analysis Set

FIGURE II

Procedure	Screening (up to 45 days prior to Day 1)	Treatment Period (Days)							Early Termination	Follow up (7-10 days post last dose) telephone call
		-1	1	2-14	15	16-27	28	29		
Visit	Visit 1	Visit 2	Visit 3		Visit 4		Visit 5	Visit 6		
Window Visit		-2 days			± 2 days		+ 4 days	+ 4 days		
Informed consent	X									
Office Visit	X	X	X		X		X	X	X	
Telephone Call ¹				X		X				
Inclusion and Exclusion criteria	X	X								
Demography	X									
Physical exam	X							X		
Medical history	X									
Pregnancy test (serum or urine) ²	X	X							X	
Urine Drug Screen	X									
Laboratory assessments ³	X	X			X			X	X	
Review screening lab assessments		X								
Bladder scan ⁴	X									
12-lead ECG	X									
Vital signs ⁵	X	X	X		X		X	X	X	
ABP Monitoring ⁶		X	X				X	X		
Witnessed Dose			X		X		X			
At Home Dose				X		X				
PK samples (PK Subset Only) ⁷					X					
AE/SAE Collection	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X		X		X	X	X	X

1. Phone call on day prior to Day 15 and Day 28 to remind subject of office visit

2. Serum pregnancy test at screening and urine test at other visits for women of childbearing potential only

3. All lab assessments will include liver chemistries and INR.

4. Vital signs will be performed on Day -1 prior to fitting the ASPM device, Day 15 prior to PK sampling, and Day 28 prior to fitting the ASPM device at 1 min intervals at least 15 minutes after arrival to the clinic but before blood draws and prior to dosing (Day 15 and Day 28).


5. Optional second visit during screening to perform bladder scan

6. Subjects will return on Day 1 and Day 29 to assess the validity of the data.

7. PK samples will be collected on Day 15 (± 2 days) at pre-dose and at 0.5, 1, 2, 3, and 4.5 hours post dose for vildagliptin concentrations (for subjects who have consented to PK sampling)


FIGURE 12

90% CI for Treatment Difference in Day 28 Change from Baseline
ABPM Systolic Blood Pressure




ABPM = Ambulatory Blood Pressure Monitoring, SBP = Systolic Blood Pressure, CI = Confidence Interval

FIGURE 13
90% CI for Treatment Difference in Day 28 Change from Baseline
ABPM Diastolic Blood Pressure




ABPM = Ambulatory Blood Pressure Monitoring, DBP = Diastolic Blood Pressure, CI = Confidence Interval



ABPM = Ambulatory Blood Pressure Monitoring, HR = Heart Rate, CI = Confidence Interval


FIGURE 15
Reduction in Micturations Over Time



Full Analysis Set Extension, CFB Least squares mean; 52-week groups only. Covariates included in the mixed model for repeated measures are study visit, treatment, treatment by study visit interaction, baseline, OAB type and sex

Baseline value is computed using the Run-in diary of parent study.


FIGURE 16
Reduction in Urinary Urge Incontinence (UUI) Episodes Over Time



Full Analysis Set Extension for Incontinence, CFB Least squares mean; 52-week groups only. Covariates included in the mixed model for repeated measures are study visit, treatment, treatment by study visit interaction, baseline and sex

Baseline value is computed using the Run-in diary of parent study.


FIGURE 17
Reduction in Urgency Episodes Over Time



Full Analysis Set, CFB Least squares mean; 52-week groups only. Covariates included in the mixed model for repeated measures are study visit, treatment, treatment by study visit interaction, baseline, OAB type and sex

Baseline value is computed using the Run-in diary of parent study.


FIGURE 18



Full Analysis Set Extension for Incontinence, CFB Least squares mean; 52-week groups only. Covariates included in the mixed model for repeated measures are study visit, treatment, treatment by study visit interaction, baseline and sex


Baseline value is computed using the Run-in diary of parent study.

FIGURE 19
Kaplan Meier Plot of Time to 75% Reduction in Urinary Urge Incontinence (UUI)



Note: Planned assessments are at Weeks 2, 4, 8 and 12

FIGURE 20
Kaplan Meier Plot of Time to 50% Reduction in Urgency



Note: Planned assessments are at Weeks 2, 4, 8 and 12. K-M estimates are unadjusted for covariates.

FIGURE 21
Plot of LS Mean (SE) of Change from Baseline Urgency in Dry Population

